{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:55:32Z","timestamp":1765486532422,"version":"3.41.2"},"reference-count":76,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/2\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Lipodystrophy syndromes cause hypertriglyceridemia that improves with leptin treatment using metreleptin. Mechanisms causing hypertriglyceridemia and improvements after metreleptin are incompletely understood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Determine relationship of circulating lipoprotein lipase (LPL) modulators with hypertriglyceridemia in healthy controls and in patients with lipodystrophy before and after metreleptin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cross-sectional comparison of patients with lipodystrophy (generalized lipodystrophy n = 3; partial lipodystrophy n = 11) vs age\/sex-matched healthy controls (n = 28), and longitudinal analyses in patients before and after 2 weeks and 6 months of metreleptin. The study was carried out at the National Institutes of Health, Bethesda, Maryland. Outcomes were LPL stimulators apolipoprotein (apo) C-II and apoA-V and inhibitors apoC-III and angiopoietin-like proteins (ANGPTLs) 3, 4, and 8; ex vivo activation of LPL by plasma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients with lipodystrophy were hypertriglyceridemic and had higher levels of all LPL stimulators and inhibitors vs controls except for ANGPTL4, with &amp;gt;300-fold higher ANGPTL8, 4-fold higher apoC-III, 3.5-fold higher apoC-II, 1.9-fold higher apoA-V, 1.6-fold higher ANGPTL3 (P &amp;lt; .05 for all). At baseline, all LPL modulators except ANGPLT4 positively correlated with triglycerides. Metreleptin decreased apoC-II and apoC-III after 2 weeks and 6 months, and decreased ANGPTL8 after 6 months (P &amp;lt; 0.05 for all). Plasma from patients with lipodystrophy caused higher ex vivo LPL activation vs hypertriglyceridemic control plasma (P &amp;lt; .0001), which did not change after metreleptin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Elevations in LPL inhibitors apoC-III and ANGPTL8 may contribute to hypertriglyceridemia in lipodystrophy, and may mediate reductions in circulating and hepatic triglycerides after metreleptin. These therefore are strong candidates for therapies to lower triglycerides in these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvaa191","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T06:37:46Z","timestamp":1607063866000},"source":"Crossref","is-referenced-by-count":9,"title":["Apolipoprotein CIII and Angiopoietin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin"],"prefix":"10.1210","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-0452","authenticated-orcid":false,"given":"Marissa","family":"Lightbourne","sequence":"first","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9479-0741","authenticated-orcid":false,"given":"Anna","family":"Wolska","sequence":"additional","affiliation":[{"name":"Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent S","family":"Abel","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-131X","authenticated-orcid":false,"given":"Kristina I","family":"Rother","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Walter","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9722-0987","authenticated-orcid":false,"given":"Yevgeniya","family":"Kushchayeva","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungyoung","family":"Auh","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D","family":"Shamburek","sequence":"additional","affiliation":[{"name":"Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan T","family":"Remaley","sequence":"additional","affiliation":[{"name":"Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-1055","authenticated-orcid":false,"given":"Ranganath","family":"Muniyappa","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-7382","authenticated-orcid":false,"given":"Rebecca J","family":"Brown","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"issue":"11","key":"2021121113033459700_CIT0001","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: Lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021121113033459700_CIT0002","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan","year":"2010","journal-title":"Endocr Pract."},{"issue":"12","key":"2021121113033459700_CIT0003","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021121113033459700_CIT0004","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med."},{"issue":"9","key":"2021121113033459700_CIT0005","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1210\/jc.2003-031868","article-title":"Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency","volume":"89","author":"McDuffie","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021121113033459700_CIT0006","first-page":"315","article-title":"Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis","volume":"119","author":"Semple","year":"2009","journal-title":"J Clin Invest."},{"issue":"9","key":"2021121113033459700_CIT0007","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1055\/s-2007-1010891","article-title":"Lipid metabolism in lipoatrophic diabetes","volume":"20","author":"Enzi","year":"1988","journal-title":"Horm Metab Res."},{"issue":"2","key":"2021121113033459700_CIT0008","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jacl.2017.02.002","article-title":"Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy","volume":"11","author":"Muniyappa","year":"2017","journal-title":"J Clin Lipidol."},{"issue":"4","key":"2021121113033459700_CIT0009","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1210\/jc.2015-3891","article-title":"Effect of leptin administration on circulating apolipoprotein CIII levels in patients with lipodystrophy","volume":"101","author":"Kassai","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021121113033459700_CIT0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest."},{"issue":"7","key":"2021121113033459700_CIT0011","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/dom.12606","article-title":"One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes","volume":"18","author":"Vatier","year":"2016","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"2021121113033459700_CIT0012","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh","year":"2013","journal-title":"J Hepatol."},{"issue":"5","key":"2021121113033459700_CIT0013","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021121113033459700_CIT0014","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J Clin Invest."},{"key":"2021121113033459700_CIT0015","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc07-S004","article-title":"Standards of medical care in diabetes--2007","volume":"30","author":"American Diabetes A","year":"2007","journal-title":"Diabetes Care."},{"issue":"8","key":"2021121113033459700_CIT0016","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/js.2019-00103","article-title":"Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy","volume":"3","author":"Kinzer","year":"2019","journal-title":"J Endocr Soc."},{"issue":"528","key":"2021121113033459700_CIT0017","doi-asserted-by":"crossref","first-page":"eaaw7905","DOI":"10.1126\/scitranslmed.aaw7905","article-title":"A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides","volume":"12","author":"Wolska","year":"2020","journal-title":"Sci Transl Med."},{"issue":"2","key":"2021121113033459700_CIT0018","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.114.220418","article-title":"A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice","volume":"352","author":"Amar","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"issue":"5","key":"2021121113033459700_CIT0019","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1210\/jc.2016-3903","article-title":"A novel APOC2 missense mutation causing apolipoprotein C-II deficiency with severe triglyceridemia and pancreatitis","volume":"102","author":"Ueda","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"2021121113033459700_CIT0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2017.10.025","article-title":"Apolipoprotein C-II: new findings related to genetics, biochemistry, and role in triglyceride metabolism","volume":"267","author":"Wolska","year":"2017","journal-title":"Atherosclerosis."},{"issue":"2","key":"2021121113033459700_CIT0021","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1210\/jc.2006-1546","article-title":"Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy","volume":"92","author":"Ebihara","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021121113033459700_CIT0022","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJM200408053510623","article-title":"Long-term leptin-replacement therapy for lipoatrophic diabetes","volume":"351","author":"Ebihara","year":"2004","journal-title":"N Engl J Med."},{"issue":"11","key":"2021121113033459700_CIT0023","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1210\/jc.2015-2589","article-title":"A report of three cases with acquired generalized lipodystrophy with distinct autoimmune conditions treated with metreleptin","volume":"100","author":"Lebastchi","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021121113033459700_CIT0024","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jc.2011-2229","article-title":"Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety","volume":"97","author":"Simha","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021121113033459700_CIT0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest."},{"issue":"6869","key":"2021121113033459700_CIT0026","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/415339a","article-title":"Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase","volume":"415","author":"Minokoshi","year":"2002","journal-title":"Nature."},{"issue":"14","key":"2021121113033459700_CIT0027","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137180","article-title":"Leptin decreases de novo lipogenesis in patients with lipodystrophy","volume":"5","author":"Baykal","year":"2020","journal-title":"JCI Insight."},{"issue":"1","key":"2021121113033459700_CIT0028","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/s41467-019-10684-1","article-title":"Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis","volume":"10","author":"Hackl","year":"2019","journal-title":"Nat Commun."},{"issue":"3","key":"2021121113033459700_CIT0029","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1172\/JCI200419511","article-title":"Site and mechanism of leptin action in a rodent form of congenital lipodystrophy","volume":"113","author":"Asilmaz","year":"2004","journal-title":"J Clin Invest."},{"issue":"7","key":"2021121113033459700_CIT0030","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1172\/JCI135431","article-title":"Free fatty acid processing diverges in human pathologic insulin resistance conditions","volume":"130","author":"Sekizkardes","year":"2020","journal-title":"J Clin Invest."},{"issue":"3","key":"2021121113033459700_CIT0031","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.ATV.19.3.472","article-title":"Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3","volume":"19","author":"Jong","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"2","key":"2021121113033459700_CIT0032","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0006-291X(72)80149-9","article-title":"Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein","volume":"46","author":"Brown","year":"1972","journal-title":"Biochem Biophys Res Commun."},{"issue":"2","key":"2021121113033459700_CIT0033","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI111711","article-title":"Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III","volume":"75","author":"Wang","year":"1985","journal-title":"J Clin Invest."},{"issue":"7","key":"2021121113033459700_CIT0034","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0022-2275(20)41415-4","article-title":"Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III","volume":"33","author":"McConathy","year":"1992","journal-title":"J Lipid Res."},{"issue":"1","key":"2021121113033459700_CIT0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Tg, Hdl Working Group of the Exome Sequencing Project NHL","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"2021121113033459700_CIT0036","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med."},{"issue":"5908","key":"2021121113033459700_CIT0037","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science."},{"issue":"25","key":"2021121113033459700_CIT0038","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJM198206243062503","article-title":"Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease","volume":"306","author":"Norum","year":"1982","journal-title":"N Engl J Med."},{"issue":"12","key":"2021121113033459700_CIT0039","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1056\/NEJMoa0907295","article-title":"Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease","volume":"362","author":"Petersen","year":"2010","journal-title":"N Engl J Med."},{"issue":"23","key":"2021121113033459700_CIT0040","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med."},{"issue":"8","key":"2021121113033459700_CIT0041","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest."},{"issue":"5","key":"2021121113033459700_CIT0042","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI112713","article-title":"Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo","volume":"78","author":"Ginsberg","year":"1986","journal-title":"J Clin Invest."},{"issue":"6","key":"2021121113033459700_CIT0043","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med."},{"issue":"5","key":"2021121113033459700_CIT0044","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med."},{"issue":"3","key":"2021121113033459700_CIT0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/nat.2016.0650","article-title":"The effects of 2\u2019-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"issue":"3","key":"2021121113033459700_CIT0046","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/ATVBAHA.110.220723","article-title":"Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia","volume":"31","author":"Caron","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"3","key":"2021121113033459700_CIT0047","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MOL.0000000000000290","article-title":"Regulation of lipid metabolism by angiopoietin-like proteins","volume":"27","author":"Dijk","year":"2016","journal-title":"Curr Opin Lipidol."},{"key":"2021121113033459700_CIT0048","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fendo.2014.00004","article-title":"Angiopoietin-like proteins: a comprehensive look","volume":"5","author":"Santulli","year":"2014","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"2","key":"2021121113033459700_CIT0049","doi-asserted-by":"crossref","first-page":"134","DOI":"10.14740\/jocmr3286w","article-title":"Relationship between angiopoietin-like protein 8 and fasting serum triglyceride level","volume":"10","author":"Yamada","year":"2018","journal-title":"J Clin Med Res."},{"key":"2021121113033459700_CIT0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-015-0324-y","article-title":"Circulating angiopoietin-like protein 8 (ANGPTL8) and ANGPTL3 concentrations in relation to anthropometric and metabolic profiles in Korean children: a prospective cohort study","volume":"15","author":"Chung","year":"2016","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"2021121113033459700_CIT0051","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MOL.0b013e328352dc70","article-title":"Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production","volume":"23","author":"Yao","year":"2012","journal-title":"Curr Opin Lipidol."},{"issue":"2","key":"2021121113033459700_CIT0052","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.yexcr.2015.09.012","article-title":"ANGPTL8\/betatrophin alleviates insulin resistance via the Akt-GSK3\u03b2 or Akt-FoxO1 pathway in HepG2 cells","volume":"345","author":"Rong Guo","year":"2016","journal-title":"Exp Cell Res."},{"key":"2021121113033459700_CIT0053","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.peptides.2018.07.001","article-title":"GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K\/Akt pathway in a GLP-1 receptor-dependent manner","volume":"106","author":"Liu","year":"2018","journal-title":"Peptides."},{"key":"2021121113033459700_CIT0054","doi-asserted-by":"crossref","first-page":"24013","DOI":"10.1038\/srep24013","article-title":"Association between betatrophin\/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep."},{"issue":"5","key":"2021121113033459700_CIT0055","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1210\/en.2016-1894","article-title":"ANGPTL8 blockade with a monoclonal antibody promotes triglyceride clearance, energy expenditure, and weight loss in mice","volume":"158","author":"Gusarova","year":"2017","journal-title":"Endocrinology."},{"issue":"6","key":"2021121113033459700_CIT0056","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00125-018-4579-1","article-title":"Angptl8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents","volume":"61","author":"Vatner","year":"2018","journal-title":"Diabetologia."},{"key":"2021121113033459700_CIT0057","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.diabres.2017.08.025","article-title":"Angiopoietin-like protein 8: an attractive biomarker for the evaluation of subjects with insulin resistance and related disorders","volume":"133","author":"Wang","year":"2017","journal-title":"Diabetes Res Clin Pract."},{"issue":"1","key":"2021121113033459700_CIT0058","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1538\/expanim.55.27","article-title":"Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity","volume":"55","author":"Fujimoto","year":"2006","journal-title":"Exp Anim."},{"issue":"37","key":"2021121113033459700_CIT0059","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J Biol Chem."},{"issue":"7","key":"2021121113033459700_CIT0060","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization","volume":"97","author":"Minicocci","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021121113033459700_CIT0061","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbrc.2004.08.024","article-title":"Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor","volume":"322","author":"Shimamura","year":"2004","journal-title":"Biochem Biophys Res Commun."},{"issue":"1","key":"2021121113033459700_CIT0062","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCGENETICS.111.959510","article-title":"Exome sequencing links gene mutation in angiopoietin-like protein 3 with low-density lipoprotein cholesterol","volume":"4","author":"Glazer","year":"2011","journal-title":"Circ Cardiovasc Genet."},{"issue":"43","key":"2021121113033459700_CIT0063","doi-asserted-by":"crossref","first-page":"41804","DOI":"10.1074\/jbc.M302861200","article-title":"Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo","volume":"278","author":"Ono","year":"2003","journal-title":"J Biol Chem."},{"issue":"48","key":"2021121113033459700_CIT0064","doi-asserted-by":"crossref","first-page":"19751","DOI":"10.1073\/pnas.1217552109","article-title":"Atypical angiopoietin-like protein that regulates ANGPTL3","volume":"109","author":"Quagliarini","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"11","key":"2021121113033459700_CIT0065","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1194\/jlr.C200010-JLR200","article-title":"Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase","volume":"43","author":"Yoshida","year":"2002","journal-title":"J Lipid Res."},{"issue":"18","key":"2021121113033459700_CIT0066","doi-asserted-by":"crossref","first-page":"11942","DOI":"10.1074\/jbc.M809802200","article-title":"A highly conserved motif within the NH2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization","volume":"284","author":"Yau","year":"2009","journal-title":"J Biol Chem."},{"issue":"46","key":"2021121113033459700_CIT0067","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1073\/pnas.0604026103","article-title":"Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue","volume":"103","author":"Sukonina","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"11","key":"2021121113033459700_CIT0068","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1210\/en.2005-0476","article-title":"Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism","volume":"146","author":"K\u00f6ster","year":"2005","journal-title":"Endocrinology."},{"issue":"6","key":"2021121113033459700_CIT0069","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2013current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol."},{"key":"2021121113033459700_CIT0070","doi-asserted-by":"crossref","first-page":"7078241","DOI":"10.1155\/2019\/7078241","article-title":"Apolipoprotein C-II mimetic peptide promotes the plasma clearance of triglyceride-rich lipid emulsion and the incorporation of fatty acids into peripheral tissues of mice","volume":"2019","author":"Komatsu","year":"2019","journal-title":"J Nutr Metab."},{"issue":"4","key":"2021121113033459700_CIT0071","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1172\/JCI117151","article-title":"Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice","volume":"93","author":"Shachter","year":"1994","journal-title":"J Clin Invest."},{"issue":"22","key":"2021121113033459700_CIT0072","doi-asserted-by":"crossref","first-page":"21553","DOI":"10.1074\/jbc.M411412200","article-title":"Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase","volume":"280","author":"Merkel","year":"2005","journal-title":"J Biol Chem."},{"issue":"5540","key":"2021121113033459700_CIT0073","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.1064852","article-title":"An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing","volume":"294","author":"Pennacchio","year":"2001","journal-title":"Science."},{"issue":"2","key":"2021121113033459700_CIT0074","first-page":"797","article-title":"Ex vivo measurement of lipoprotein lipase-dependent very low density lipoprotein (VLDL)-triglyceride hydrolysis in human VLDL: an alternative to the postheparin assay of lipoprotein lipase activity?","volume":"86","author":"Pruneta","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021121113033459700_CIT0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0009-8981(95)06032-3","article-title":"Human triacylglycerol-rich lipoprotein subfractions as substrates for lipoprotein lipase","volume":"236","author":"Fisher","year":"1995","journal-title":"Clin Chim Acta."},{"issue":"32","key":"2021121113033459700_CIT0076","doi-asserted-by":"crossref","first-page":"20554","DOI":"10.1016\/S0021-9258(17)32029-X","article-title":"Kinetics of lipolysis of very low density lipoproteins by lipoprotein lipase. Importance of particle number and noncompetitive inhibition by particles with low triglyceride content","volume":"269","author":"Connelly","year":"1994","journal-title":"J Biol Chem."}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaa191\/34694501\/bvaa191.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/5\/2\/bvaa191\/41724987\/bvaa191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/5\/2\/bvaa191\/41724987\/bvaa191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T13:04:43Z","timestamp":1639227883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaa191\/6020013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaa191","relation":{},"ISSN":["2472-1972"],"issn-type":[{"type":"electronic","value":"2472-1972"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2020,12,4]]},"article-number":"bvaa191"}}